LeMaitre Vascular, a $117.2m maker of specialized catheters, shunts and grafts to treat peripheral vascular disease has acquired Artegraft, Inc., a developer of bovine carotid artery-derived biologic grafts used to treat hemodialysis access patients, for $72.5m upfront and milestones of up to $17.5m. Artegraft’s sales grew 10% in 2019. During the trailing 12 months ended 5/31/20, Artegraft generated trade sales of $15.6m and estimated hospital-level revenue of $18.6m. The acquisition augments LeMaitre’s existing suite of biologic and dialysis access products used to treat patients with end-stage renal disease.
Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare mergers, Medical Devices